Key facts
- It has raised $27.6M; the latest was Secondary Transaction - Private in Apr 2026.
- Notable investors include Suzhou Oriza Holdings Corporation, Cowin Capital, Leader Venture Capital, Peiyang Begonia Fund, China Reform Holdings Corporation — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Agile Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Agile Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Agile Bio
Manufacturer of laboratory and bioprocess separation systems designed to enable efficient extraction, separation, and purification in biomedical and diagnostic workflows. The company offers separation materials, fluid automation systems, and online detection technologies with integrated automation and certified quality standards, enabling biopharmaceutical, clinical testing, and food testing laboratories to improve process accuracy, reliability, and operational efficiency in sample preparation and analysis.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2020
- Employees
- 33
- Website
- agilebio.com.cn/
- Ownership
- Privately Held (backing)
Agile Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Agile Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Agile Bio in its N-PORT filings yet. We sweep new filings monthly.